Cargando…
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current...
Autores principales: | Martora, Fabrizio, Megna, Matteo, Battista, Teresa, Potestio, Luca, Annunziata, Maria Carmela, Marasca, Claudio, Villani, Alessia, Fabbrocini, Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869696/ https://www.ncbi.nlm.nih.gov/pubmed/36698446 http://dx.doi.org/10.2147/CCID.S391356 |
Ejemplares similares
-
Secukinumab and hidradenitis suppurativa: Friends or foes?
por: Marasca, Claudio, et al.
Publicado: (2019) -
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis
por: Martora, Fabrizio, et al.
Publicado: (2023) -
Teledermatology in the management of hidradenitis suppurativa: Should we improve this service?
por: Ruggiero, Angelo, et al.
Publicado: (2022) -
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023) -
A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa
por: Marasca, Claudio, et al.
Publicado: (2018)